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TO THE EDITOR Cytogenetic analysis of B-precursor ALL at presentation and subsequent relapse frequently reveals subclonal evolution and increasing karyotypic complexity. The emergence of an entirely independent cytogenetically abnormal clone at relapse compared with presentation, however, is an extremely rare event in both paediatric and adult ALL. 1 In fact, a proportion of those rare cases show the emergence of 11q23 abnormalities, and presumed MLL gene rearrangement, during disease progression which, in non-infant cases, is more likely to represent DNA-topoisomerase II inhibitor-induced secondary leukaemia rather than relapse of the primary disease. 1 Minor alterations in immunophenotype are a relatively more common feature of this malignancy, although only 10% of cases exhibit intra-lineage shifts between presentation and relapse. 2 We report the unusual case of a B-precursor ALL exhibiting both an intra-lineage shift and a complete change in cytogenetic karyotype between diagnosis and relapse. A 12-year-old girl presented with lethargy, shortness of breath, weight loss and pallor. Investigations revealed a white cell count (WCC) of 58.9 × 10 9 /l, haemaglobin (Hb) at 2.6 g/dl and platelets at 70 × 10 9 /l, with numerous blast cells on the peripheral blood smear. A marrow aspirate confirmed the diagnosis of acute lymphoblastic leukaemia (FAB type L1). Immunophenotyping of the diagnostic bone marrow sample showed a pre-B ALL phenotype that was surface positive for CD19, CD22, CD24, HLA-DR, CD45 and weakly positive for CD5; surface negative for CD10, CD79b, CD34, CD13 and CD33; cytoplasmic positive and nuclear TdT negative. Analysis of G-banded chromosomes from diagnosis identified eight metaphase cells with a pseudo-diploid karyotype of 46,XX,add(2)(q3?),del(6)(q1?),add(9)(p?2) and two cells exhibiting an apparently normal female karyotype. Additional interphase and metaphase FISH analyses were performed (Leukaemia Research Fund ALL Database Laboratory, Royal Free Hospital, London, UK) and showed no evidence of a TEL/AML1 or MLL gene rearrangement at diagnosis. Furthermore, the presence of a cytogenetically cryptic BCR/ABL rearrangement was excluded by RT-PCR. The patient was treated according to the Medical Research Council (MRC) ALL97 high risk protocol and was randomised to receive prednisolone, cranial radiotherapy and 6-mercaptopurine.
Nineteen months later, during maintenance chemotherapy, relapse of the leukaemia was diagnosed. Immunophenotyping revealed a more immature pro-B cell phenotype of the blast cells that were surface positive for CD19, CD22, HLA-DR and CD5 but surface negative for CD45, CD10, CD34, CD13 and CD33; cytoplasmic CD79a positive; cytoplasmic negative and nuclear TdT positive. Fifty percent of the blasts at relapse were positive for CD15. Interestingly, chromosome analysis identified nine cells with a high-hyperdiploid karyotype of 56,XX,+6,inv(13)(q14q34),+inv(13)(q14q34),+14,+16,+18,+20, +20,+21,+21,+22 In an effort to establish a clonal relationship between the leukaemic populations from diagnosis and relapse, PCR analysis of the IgH gene rearrangements was performed. Amplification of the IgH CDRIII region from tumour cDNA and DNA using Fr3A/J1H consensus primers revealed the presence of the same clonal VDJ H gene rearrangement both at diagnosis and relapse (Table 1 ). In addition, PCR amplification of the TCR␦ gene region from the same material identified the presence of two different clonal TCR␦ rearrangements, TCR V␦2-D␦3 (d) and TCR V␦2-D␦3 (r), at diagnosis and relapse, respectively (Table 1) . Interestingly, the clonal IgH rearrangement common to both the diagnostic and relapse clones did not contain non-template 'N' nucleotides inserted at the D-J H join (Table 1) . This is a common feature of rearrangements generated during foetal development due to the low expression of the enzyme TdT 3 and suggests that the clonal proliferation originated in utero. Similarly, despite the more mature pre-B cell immunophenotype of the presenting tumour population, the diagnostic TCR␦ gene rearrangement, TCR V␦2-D␦3 (d), resembled an immature recombination with virtually no junctional diversity (Table  1 ). In contrast, the relapse TCR␦ rearrangement, TCR V␦2-D␦3 (r), exhibited extensive non-template nucleotide insertion typically associated with adult VDJ rearrangements, suggesting temporal differences between the two clonal populations (Table 1) .
Taken together, the presenting and relapsing populations in this leukaemia represent the same clonal disease characterised by a common IgH rearrangement where extensive clonal diversity resulted in the occurrence of a completely independent karyotype and an intra-lineage shift in immunophenotype. Combining the cytogenetic, immunophenotypic and immune system gene rearrangement analyses (Figure 1 ), it appeared that the leukaemia arose from a fully IgHrearranged B-precursor, most likely during an early stage of foetal development characterised by low TdT activity. 3 The configuration of the clonal TCR V␦2-D␦3 (d) rearrangement from diagnosis was also consistent with a prenatal origin (see Table 1 ), although we could not exclude the possibility that the lack of TCR␦ junctional diversity was due to the absence of TdT activity in the corresponding pre-B cell tumour population. It was not possible to establish, however, at which point prior to disease presentation the diagnostic pseudo-diploid karyotype arose (Figure 1) . Furthermore, it is also not clear whether the relapsing high-hyperdiploid karyotype occurred early in leukaemogenesis prior to diagnosis or was generated later, between diagnosis and relapse. However, given the absence of any high-hyperdiploid cells at diagnosis, determined by conventional cytogenetic analysis of 20 metaphase cells and FISH analysis of 100 interphase nuclei as well cytogenetic analysis of 45 metaphase cells at 7 days post-induction therapy, it is likely that the high-hyperdiploid karyotype from relapse was generated in the short period between diagnosis and relapse 
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Figure 1
Model for clonal evolution. The leukaemia was probably initiated in utero generating a 'pre-leukaemic' clone carrying a common IgH gene rearrangement. Clonal divergence subsequently enabled the independent rearrangement of the TCR V␦2-D␦3 genes and acquirement of cytogenetic abnormalities. The diagnostic pre-B population could have arisen in utero, judged by the lack of junctional diversity in the corresponding TCR gene rearrangement, TCR V␦2-D␦3 (d). The relapsing pro-B tumour population probably did not arise until after diagnosis, judged by the absence of high-hyperdiploid cells in the diagnostic tumour population and the junctional diversity of the corresponding clonal TCR gene rearrangement, TCR V␦2-D␦3 (r). (Thick arrows indicate major clonal proliferation at diagnosis and relapse.) (Figure 1) . Indeed, the clonal TCR rearrangement from relapse, TCR V␦2-D␦3 (r), was consistent with a more mature recombination (see Table 1 ), supporting evolution of the relapsing clone in adult haematopoiesis. Therefore, the likely foetal initiation of this leukaemia together with its presentation in later childhood suggests an extremely protracted latency and supports Greaves' two-step hypothesis for the pathogenesis of B-precursor ALL.
Intra-lineage shifts between presentation and relapse are rare in paediatric B-precursor ALL. 2 Interestingly, in our patient we detected a shift from a pre-B ALL at diagnosis to a pro-B immunophenotype at relapse. The two leukaemic populations differed significantly with respect to the expression of cytoplasmic , nuclear TdT as well as surface CD45. Absence of CD45 expression was previously reported in association with hyperdiploidy, 4 an observation consistent with our findings at relapse. In contrast, the expression of markers CD19, CD22, HLA-DR and CD5 remained constant. CD5 was the most atypical antigen expressed in this leukaemia and was consistently aberrantly expressed both at presentation and relapse, suggesting an association between the two clones. The role of CD5, which is rarely detected in paediatric B-precursor ALL, is largely unknown but it has been associated with auto-immunity as well as activation and differentiation, rather than lineage commitment.
5 Interestingly and consistent with our findings, Subira et al 5 and Balduzzi et al 6 both reported coexpression of CD19 and CD5 in two unusual cases of aggressive paediatric B-precursor ALL one of which demonstrated two immunophenotypic shifts. 6 The emergence of an apparently entirely independent cytogenetic karyotype observed at the relapse of our leukaemia is also a very unusual occurrence in B-precursor ALL. Previously, Abshire et al 7 described only 1/116 cases with an apparently independent karyotype at relapse and Raimondi et al 1 described 9/98 cases with entirely different karyotypes at relapse, of which three acquired 11q23 abnormalities, suggesting secondary ALL. Only one case demonstrated a significant shift in ploidy while the remaining tumours all maintained a near-diploid karyotype between diagnosis and relapse. 1 Pseudo-diploid karyotypes are reported in 29% of childhood B-precursor ALL and are often associated with both a high presenting WCC and poor prognosis 8 although they can display either high-risk or low-risk associated chromosome abnormalities. The pseudo-diploid karyotype at the diagnosis of our case did not have clear prognostic significance. Deletion of chromosome 6q, present at the diagnosis of this leukaemia, is not associated with adverse risk and is considered to be an early event in leukaemogenesis, while abnormalities of chromosome 9p21, also detected in our leukaemia, are less frequent and implicated in disease progression. 8 The case presented demonstrates the difficulty in predicting the clinical behaviour of paediatric B-precursor ALL, which, in terms of pathogenesis, may well represent a heterogeneous disease. Although this leukaemia was treated as high-risk, due to the age of the patient and high WCC at diagnosis, the emergence of a 'good prognostic' hyperdiploid karyotype at relapse, in particular, illustrates the requirement for careful consideration in the prognostic evaluation of paediatric ALL. Furthermore, minimal residual disease (MRD) is rapidly being recognised as a powerful predictive tool for disease management. In this case, two leukaemic clonal determinants (karyotype and immunophenotype) conventionally used to measure MRD in paediatric ALL were unstable. In addition, although the clonal IgH gene rearrangement did remain stable in our case, immune system gene rearrangements are notoriously unstable clonal markers in aggressive ALL. Therefore, as an extensive phenotypic versatility appears to be a feature of aggressive leukaemias, future efforts could be well directed towards the recognition of these aggressive leukaemias at their presentation. Notably, CD5 was consistently present throughout this disease. Albeit rarely expressed in paediatric B-precursor ALL tumours, CD5 expression may emerge as a novel indicator of unstable, aggressive disease. TO THE EDITOR Cystathionine-␤-synthase (CBS; gene localized to 21q22.3), a pyridoxal 5′-phosphate-dependent enzyme involved in the transsulfuration pathway, catalyzes the condensation of serine and homocysteine to form cystathionine, an intermediate step in the synthesis of cysteine. CBS enzyme deficiency results in the autosomal recessive disorder, homocystinuria, characterized by mental retardation, lens dislocation, skeletal abnormalities, elevated plasma and urine homocysteine levels, and an increased risk of thromboembolism and early onset atherosclerosis. Approximately 100 mutations in the CBS gene associated with homocystinuria have been identified, the majority of which are missense mutations. Hyperhomocysteinemia, a risk factor for atherosclerosis, is also associated with the heterozygous carrier state of CBS mutations. The two most frequent point mutations in the CBS gene occur in exon 8: (1) a T 833 C transition substituting a threonine for isoleucine at codon 278 [I278T] and (2) a G 919 A transition, substituting a serine for glycine at codon 307 [G307S]. The most common variation in the CBS gene, a polymorphism involving a 68-bp insertion (844ins68) in the coding region of exon 8, results in a duplication of the intron-exon boundary of exon 8 (53 nt and 15 nt upstream and downstream of the splicing site, respectively), which produces an alternate splice site. 1 The T 833 C mutation is also present in all alleles that contain the 844ins68 polymorphism. The frequency of the 844ins68 allele is variable and has been identified at a frequency of 11.7% in normal North American populations. 1 We previously documented an important relationship between CBS expression/activity and increased in vitro and in vivo sensitivity to cytosine arabinoside (ara-C), which contributes to the significantly high event-free survival (EFS) rates of DS children with acute myeloid leukemia (AML). 2, 3 In this study, we examined the frequency of the 844ins68 CBS polymorphism and point mutations in CBS exon 8 in myeloblast samples from DS and non-DS children with AML, and in mononuclear cells from healthy, non-leukemic DS children. Myeloblasts from newly diagnosed pediatric AML patients were obtained from the Children's Hospital of Michigan cell bank and from patients treated on the Pediatric Oncology Group (POG) 9421 chemotherapy protocol as previously reported.
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2 Genomic DNA samples from healthy, non-leukemic DS children were obtained by venipuncture. Genomic DNAs were extracted from buccal swabs of healthy adult subjects. The research protocol was approved by the Human Investigation Committee of Wayne State University.
CBS exon 8 was amplified in genomic DNAs from myeloblasts of DS and non-DS AML patients, healthy non-leukemic DS individuals and healthy adults using sense (5′-GCATGTCCAGGCGGGGCTTTTG CTG-3′) and antisense (5′-ACTGTGGCCGGGCTCT-GGACTCGAC Total RNAs were isolated from patient myeloblasts using TRIzol reagent. First-strand cDNAs were synthesized as previously reported. 2 To obtain adequate amplification of CBS cDNAs containing exon 8, semi-nested PCR reactions were performed using sense (5′-TGCCTCC GAGTCCCCACATCACCA-3′ and 5′-GCACTGGGGGCTGAGATTGT GAGGAC-3′) and antisense (5′-CGCCTCCTCATCGTTGCTCTTGAAC CAC-3′) primers. Final PCR products (447 bp) were isolated with the Concert Rapid Gel Extraction Kit (Life Technologies, Rockville, MD, USA) from a 1.5% agarose gel stained with ethidium bromide and sequenced. The Fisher's exact test was used to compare the frequencies of the CBS 844ins68 polymorphism and wild-type CBS exon 8 sequence between the different patient groups and differences in ara-C IC 50 values were compared between the groups utilizing the Mann-Whitney test.
The 844ins68 polymorphism was detected at a 4.6-fold (P Ͻ 0.001) higher frequency in DS myeloblasts compared to non-DS myeloblasts ( Table 1 ). The gene variant was also detected in genomic DNA samples from healthy control subjects, similar to the non-DS myeloblasts and consistent with the frequencies reported previously in the general population (Table 1) . 1 The polymorphism was detected in an approximately two-fold higher frequency in blood samples from healthy, non-leukemic DS individuals compared to the non-leukemic DS population. The difference between the frequencies of the polymorphism in DS myeloblasts and non-leukemic DS blood samples was also statistically significant (P = 0.04). In all the DS and non-DS cases Table 1 Frequency of the CBS 844ins68 polymorphism in Down syndrome and non-Down syndrome populations DS AML non-DS AML Healthy Healthy non-(%) (%) DS (%) DS (%) 844ins68 10 (52.6) 5 (11.4) 13 (24.1) 2 (10) + 844ins68 9 (47.4) 39 (88.6) 41 (75.9) 18 (90) − Genomic DNA of both leukemic and non-leukemic individuals was amplified to determine the frequency of the CBS 844ins68 polymorphism between Down syndrome and non-Down syndrome populations.
